Swine Flu Stocks Moving Markets at Mid Week

Swine Flu Stocks Moving Markets at Mid Week Sep. 24, 2009 (Baystreet.ca) -- A number of people have been ranting about that biotech drug company we all nearly forgot about, CEL-SCI (AMEX:CVM). The company has seen it's shares rise during the last few weeks, all based on what has been described as a "perfect storm" of developments. The stock has shown incredible bullishness (up 408.77% this year) but it suffered a bit of consolidation despite some news today. Blame the bad market day or the bashers? Neither. This stock is still way undervalued but no stock in the history of the world has ever gone straight up forever and even the worst stocks stop to take a breather on the way down to zero. Look for this one to keep rising as people continue to discover all the great things the company has cooking, especially now that they finally have some money to move some of their pipeline along into various other phases and trials. Some are wondering just how real some of these developments about their H1N1 treatment are. I think the FDA's vote counts more than all of ours combined and it seems to spell out very clearly: "It's real!" One article, by the same news portal that's been following this stock all the way up the charts, went out of it's way to tell it's readers that desperate times call for desperate measures in a somewhat long-winded, yet well researched kind of way. Let me make it as simple as possible. This is a world wide pandemic. And yes, CNN's Dr. Sanjay Gupta (the same man once in line to be U.S. Surgeon General) who is in a hospital recovering from a bout with the swine flu say it's real too. "This is the sickest I have ever been," he said today. CEL-SCI knew that when they went to work on this treatment years ago. Forget that it was originally designed to treat something else, their "aha moment" may have come just in time to save us all. Some of the best drug treatments are born that way. The way we hear it, the FDA may very well issue Emergency Use Authorization (EUA) for this drug candidate. Already they've handed the company something that usually takes years and mountains of paperwork to get. Don't be surprised one bit to see the CDC request and the FDA-issue an Emergency Use Authorization (EUA) letter just like they did for Tamiflu (oseltamivir), Relenza (zanamivir) and a host of other drugs and screening devices no one has ever heard of. That golden ticket, disguised in the form of a letter, will allow either the use of an unapproved medical product or an unapproved use of an approved medical product during certain types of emergencies. We already know that government agents have been crawling all over the facilities at CEL-SCI and they didn't have to drive very far, since the company is located at the outskirts of D.C. Either way, it seems to us that the Health and Human Services Secretary is well aware of the situation as is making sure as quickly as possible that all the statutory criteria have been met. It happens a lot more often than you'd think and all the signs say "Pass Go, Collect $200" or a few billion more. A little more suspicious to me are the developments involving XOMA Ltd. (Nasdaq:XOMA) and their timely press release that announced the development of their own influenza treatment. I think I would have been more inclined to buy into the news, literally, if they had told me about this before they got their anticipated deficiency notice from NASDAQ a couple of days ago. Ta-dah! Back over a dollar today... By one cent... Just like that. Know this. The government agency listed on their press release wasn't the FDA and I doubt any of us had ever heard of it before today. Also, CEL-SCI didn't send out a press release when all those secret meetings with the government were going on. That was a leak they had to plug wasn't it? Call me cynical. In other news, The New England Journal of Medicine published some results from TEVA PHARM's (PINK:TEVJF) ADAGIO study with AZILECT. They demonstrated that Parkinson's disease patients receiving AZILECT (rasagiline) 1mg/day at the start of the study experienced superior benefit over 18 months compared with those who started the exact same treatment nine months later. According to the experts there, this finding shows a clear and possible disease-modifying effect for AZILECT (rasagiline) 1mg/day. Also, an FDA Advisory Committee heard presentations and public comments about Neuromed Pharmaceuticals Inc and Covidien's (NYSE:COV) plan to limit potential abuse of their once-a-day painkiller Exalgo. Apparently they liked what they heard. They agreed that Exalgo does help patients feel better but they said the companies needed to closely watch how the drug was used, because it was a "much much better" kind of feeling. Neuromed, which is expected to finalize its merger with CombinatoRx (NASDAQ:CRXX) later this year.

The release as fetched from its publisher. cel-sci.com ↗